TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

As a global contract research organization, Creative Biolabs established one-stop CAR-T cell therapy development solutions to advance your CAR-T cell product candidate. We offer comprehensive solutions distinctly for the progressive biopharma venture. To build more powerful CAR-T cells, we have developed TRAC-CAR T cell with CRISPR/Cas9 technology.

Challenges for Conventional CAR-T Cell

TRAC CAR-T Cell Development with CRISPR Cas9 Technology

CAR-T cell therapy has shown significant efficacy in the treatment of acute leukemia and non-hodgkin lymphoma, etc., thus considering to be one of the most promising cancer immunotherapies. While some existing disadvantages need to be improved for making more efficient CAR-T cells.

For conventional CAR-T cells, CAR genes are transferred into the T cell genome by retroviruses or lentiviruses. They can cause CAR genes to be randomly inserted into the locus of genome which may elicit potential genetic side effects.

CRISPR/Cas9 Technology

RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/Cas9 has demonstrated great potential for precise genetic manipulation. CRISPR/Cas9 has significantly hit the headlines as a powerful tool that is dramatically changing the way scientists are advancing researches. CRISPR technology can deliver a CAR gene to a very specific location (TRAC) in the genome of the T cell. This precise approach resulted in CAR-T cells with more stamina.

Advantages of CRISPR/Cas9 Technology

Cost effective,
Integration-free,
Capacity for mutating multiple genes in a single system

TRAC-CAR-T Cell Development Services

TRAC CAR-T Cell Development with CRISPR Cas9 Technology Fig.1 CRISPR/Cas9-targeted CAR gene integration into the TRAC locus. (Eyquemc, 2017) Utilizing the CRISPR/Cas9 technology that holds great promise as an efficient gene knock-in platform, we have developed end-to-end CRISPR/Cas9 services to directing the specific CARs to the T-cell receptor α constant (TRAC) locus (see Fig.1). Compared with conventional CAR-T cells, TRAC-CAR T cells exhibit uniform CAR expression which results in enhanced T cell potency and safety profile. Our TRAC-CAR T platform will advance your desired immunotherapies through CRISPR/Cas9 genome editing which is more precise. Leverage the CRISPR to build CAR-T cells, the genomic engines will run more smoothly, which means TRAC-CAR T cells rack up more trouble-free miles with long-distance races.

CRISPR/Cas9 Service Process

TRAC CAR-T Cell Development with CRISPR Cas9 Technology

NR4A Knock Out CAR-T Cell Development with CRISPR Technology

Leverage the expertise of our experienced scientists to expedite and innovate your therapeutic CAR-T projects, we are inspired by NR4A target and are dedicated to providing NR4A knock out CAR-T cell development services.

TRAC-CAR-T Cell Advantages

TRAC CAR-T Cell Development with CRISPR Cas9 Technology

Expressed CARs homogeneously and consistently at an optimal baseline level that offered improved antitumor efficacy.
Reduced tonic activation signaling and developed effective internalization and balanced re-expression of the CAR upon single or repeated antigen exposure.
Retained a naive/central memory phenotype, delayed effector T cell differentiation and exhaustion, making them better effector cells.
Improved safety profile. (Because the lack of TCRs reduces the risk of TCR-induced alloreactivity and autoimmunity, and the precisec insertion of the CAR coding sequence reduces the risk for insertional oncogenesis.)

To accelerate your CAR-T project, develop engineered T cell with precise CAR insertion, Creative Biolabs offers an end-to-end CRISPR/Cas9 solution that holds immense promise for advancing immunotherapy. We combine the traditional and the most advanced CRISPR/Cas9 genetic manipulation technology to efficiently produce more powerful CAR-T cells addressing urgent unmet medical demands. Please feel free to contact us to learn how we can be involved in your project.

Reference

Eyquem, Justin, et al. "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection." Nature 543.7643 (2017): 113.